V1a Selective Triazole Derivatives for Renal Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the vasopressin V1a receptor lack sufficient selectivity and potency, leading to unwanted side effects and fluid homeostasis dysregulation, particularly in treating renal and cardiovascular diseases where decongestion is not desired.
Innovation Solution
Development of 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives that act as highly potent and selective antagonists of the V1a receptor, avoiding V2 receptor inhibition to prevent aquaresis and offering improved therapeutic profiles compared to prior art.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds targeting the vasopressin V1a receptor are used, then some therapeutic effect is achieved, but selectivity is insufficient leading to unwanted side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the triazole ring and pyridinyl group. The carboxamide group at position 5 and specific substituents at positions R1-R6 create localized chemical features that enhance V1a receptor selectivity while maintaining therapeutic activity, thereby reducing unwanted side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (hydroxyl, fluorine, chlorine, methyl), substituent positions (R1-R6), and molecular structure characteristics. These parameter modifications optimize the balance between therapeutic efficacy and selectivity, reducing harmful side effects while maintaining desired pharmacological activity.
2Reliability
If current compounds are used to treat renal and cardiovascular diseases, then some therapeutic benefit is achieved, but fluid homeostasis is dysregulated causing decongestion
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the triazole ring and pyridinyl group. The carboxamide group at position 5 and specific substituents at positions R1-R6 create localized chemical features that enhance V1a receptor selectivity while maintaining therapeutic activity, thereby reducing unwanted side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (hydroxyl, fluorine, chlorine, methyl), substituent positions (R1-R6), and molecular structure characteristics. These parameter modifications optimize the balance between therapeutic efficacy and selectivity, reducing harmful side effects while maintaining desired pharmacological activity.
3Reliability
If V2 receptor inhibition is achieved to increase urine excretion, then water homeostasis is improved, but decongestion occurs which is unwanted in certain disease conditions
Solution Approach 1:
The patent applies segmentation by separating the pharmacological effects on different vasopressin receptor subtypes. The compounds are designed to selectively target V1a receptors while sparing V2 receptors, achieving segmentation of receptor activity. This allows improvement of water homeostasis through V1a selectivity without causing unwanted decongestion that would result from V2 inhibition.
Solution Approach 2:
The patent applies local quality by introducing specific substituent patterns at defined positions on the triazole ring and pyridinyl group. The carboxamide group at position 5 and specific substituents at positions R1-R6 create localized chemical features that enhance V1a receptor selectivity while maintaining therapeutic activity, thereby reducing unwanted side effects.
Data Source
AI summary
The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.